Reviva to Participate in the 2025 BIO CEO & Investor Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH), a late-stage pharmaceutical company focused on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases, has announced its participation in the 2025 BIO CEO & Investor Conference.
The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will be part of a panel discussion titled 'Tackling Mental Health through New Targets and Endpoints Progress'. The panel is scheduled for Tuesday, February 11, 2025, at 1:00 p.m. ET in New York, NY.
The conference will take place from February 10-11, 2025, and interested parties can register for the event and schedule one-on-one meetings with Reviva's management team.
Details
News Market Reaction – RVPH
The recorded move for RVPH in the trading session of this news was +2.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking place February 10-11, 2025, in New York, NY.
2025 BIO CEO & Investor Conference
Panel Title: Tackling Mental Health through New Targets and Endpoints Progress
Date: Tuesday, February 11, 2025
Time: 1:00 p.m. ET
Location: New York, NY
To register for the conference and schedule a one-on-one meeting with Reviva management, please use the link HERE.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.